Send this to a friend

Mustang Bio to process rare cancer drug in Worcester

New York biotech Mustang Bio is already putting its new Worcester facility to use, as the lab will help the company process a new drug to treat a rare and incurable cancer.
The company announced Thursday an Orphan Drug Designation from the U.S. Food and Drug Administration for MB-102, which the company hopes can treat blastic plasmacytoid dendritic cell neoplasm (BPDCN), a deadly blood cancer with a medial survival less than 18 months.
Mu ...

Fields marked in red are required
Your name
Your email
Recipient addresses
(Separate multiple addresses with commas)

Personal message

Copyright 2017 New England Business Media